Loading
A phase 1/2 trial of Fludarabine and Cyclophosphamide in gastric & gastro-oesophageal junction cancer, run by Beijing Biotech, now recruiting.
Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer is a phase 1/2 interventional study registered as NCT07551362 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DT-CAR-NK, Fludarabine and Cyclophosphamide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/